Please assess the completion status of the following clinical trial:

Trial Title: To Evaluate the Immunogenicity and Safety of 'BR-TD-1001' Administered Intramuscularly in Healthy Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy boys and girls aged 10 to 12 years~2. Those who received primary immunization (5 doses of diphtheria and tetanus vaccination until the age of 6)~3. Voluntary written consent of the subject and the legally acceptable representative(LAR) to participate in this clinical study~Exclusion Criteria:~1. 2 weeks have not passed since recovery from an acute disease~2. Temporary thrombocytopenia or neurological complications due to diphtheria or tetanus vaccination~3. History of a severe allergy to any component of the investigational product~4. History of a severe adverse event due to administration of diphtheria, tetanus, or diphtheria tetanus combined vaccine~5. Administration of tetanus, diphtheria, or diphtheria tetanus combined vaccine within 5 years~6. Unable to verify diphtheria and tetanus vaccination completed until the age of 6~7. History of infection with diphtheria or tetanus (if clinically, serologically or microbiologically confirmed)~8. Current chronic disease that impedes implementation or completion of the clinical study~9. Scheduled surgery during the study period~10. Acute fever with a tympanic temperature exceeding 38.0ºC within 72 hours before administration of the investigational vaccine~11. Administration of other vaccines within 28 days before screening~12. Use of immunosuppressants or immune modifying drugs within 3 months before screening~13. Those who have received immunoglobulin therapies or blood derived products within 3 months before screening, or are expected to receive them during the study period~14. Use of antipyretics/analgesics/nonsteroidal anti inflammatory drugs within 4 hours before administration of the investigational vaccine~15. Participation in other clinical studies within 28 days before screening~16. Those who were determined by the investigator to be ineligible for other reasons

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 12 Years
- Healthy Volunteers: t

Study Arms:
- BR-TD-1001 (Type: EXPERIMENTAL): Randomized subjects were assigned to receive a single dose of BR-TD-1001
- Td-pur inj (Type: ACTIVE_COMPARATOR): Randomized subjects were assigned to receive a single dose of Td-pur inj

Based on this trial design, predict the completion outcome and termination type (if applicable).